Related Experiment Videos
Clinical outcome in four children with metachromatic leukodystrophy treated by bone marrow transplantation
G Malm1, O Ringdén, J Winiarski
1Department of Paediatrics, Huddinge University Hospital, Sweden.
Abstract:
Four children with metachromatic leukodystrophy (MLD) underwent allogeneic bone marrow transplantation between 1988 and 1993. No effect on the natural course of the disease was observed in two children with late infantile and juvenile MLD. They had moderate neurological symptoms at the time of BMT and were followed for 7 and 6 years, respectively. The third child with the juvenile form of MLD was mildly to moderately affected when transplanted. She had lost some gross motor functions as well as speech and mental abilities at follow-up 3 years later. The fourth case, diagnosed biochemically and presymptomatically as late infantile MLD, had a subtle gait disturbance when grafted at 18 months of age. Demyelination, not observed before BMT, was visualized 1 year later on MRI. This boy's condition has continued to deteriorate 2 years after transplantation. We have adopted recent recommendations that BMT should be considered only in presymptomatic children with late infantile MLD or early in the course of juvenile MLD. In such children, still longer follow-up periods are necessary to evaluate the benefit of BMT.
Insights
Allogeneic bone marrow transplantation (BMT) showed no benefit for children with moderate metachromatic leukodystrophy (MLD). BMT may only be considered for presymptomatic or early-stage MLD, requiring longer follow-up.
Area of Science:
- Neurology
- Pediatrics
- Hematology
Background:
- Metachromatic leukodystrophy (MLD) is a rare genetic disorder affecting the nervous system.
- Allogeneic bone marrow transplantation (BMT) is a potential treatment for certain genetic disorders.
Observation:
- Four children with MLD received BMT between 1988 and 1993.
- Outcomes were evaluated based on disease severity at the time of transplantation and follow-up duration.
Findings:
- BMT did not alter the disease course in two patients with late infantile and juvenile MLD who had moderate neurological symptoms.
- A third patient with juvenile MLD experienced neurological decline post-BMT.
- A presymptomatic patient with late infantile MLD showed disease progression, including MRI-detected demyelination, after BMT.
Implications:
- Current BMT protocols for MLD should be re-evaluated.
- Consideration for BMT in MLD should be limited to presymptomatic or very early juvenile stages.
- Longer follow-up studies are essential to determine the true efficacy of BMT in MLD.